Gilead Sciences Announces First Quarter 2013 Financial Results

  Gilead Sciences Announces First Quarter 2013 Financial Results

   - Product Sales of $2.39 billion, Up 8 percent over First Quarter 2012 -

  - Total Revenues of $2.53 billion, Up 11 percent over First Quarter 2012 -

                    - Reiterates Full Year 2013 Guidance -

Business Wire

FOSTER CITY, Calif. -- May 02, 2013

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations
for the quarter ended March 31, 2013. Total revenues for the first quarter of
2013 increased 11 percent to $2.53 billion, from $2.28 billion for the first
quarter of 2012. Product sales increased 8 percent to $2.39 billion for the
first quarter of 2013 compared to $2.21 billion for the first quarter of 2012.
Net income for the first quarter of 2013 was $722.2 million, or $0.43 per
diluted share compared to $442.0 million, or $0.28 per diluted share for the
first quarter of 2012. Non-GAAP net income for the first quarter of 2013,
which excludes acquisition-related, restructuring and stock-based compensation
expenses, was $801.9 million, or $0.48 per diluted share compared to $704.4
million, or $0.45 per diluted share for the first quarter of 2012.

                                            Three Months Ended
                                             March 31,
                                             2013           2012
Product sales                                $ 2,393,568     $ 2,208,342
Royalty, contract and other revenues         138,067        74,107
Total revenues                               $ 2,531,635    $ 2,282,449
                                                             
Net income attributable to Gilead            $ 722,186       $ 441,956
Non-GAAP net income attributable to Gilead   $ 801,943       $ 704,389
                                                             
Diluted EPS                                  $ 0.43          $ 0.28
Non-GAAP diluted EPS                         $ 0.48          $ 0.45
                                                               

Product Sales

The increase in product sales during the first quarter of 2013 was due
primarily to Gilead's antiviral franchise, resulting from increased sales of
Complera^®/Eviplera^® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir
disoproxil fumarate 300 mg) and the launch of Stribild^® (elvitegravir 150
mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300
mg) in the third quarter of 2012.

Antiviral Product Sales

Antiviral product sales increased 7 percent to $2.06 billion for the first
quarter of 2013, up from $1.93 billion for the first quarter of 2012,
reflecting sales growth of 8 percent in Europe and 7 percent in the U.S. The
increase reflects strong underlying demand, specifically for Complera/Eviplera
and Stribild, partially offset by a decrease in sales of Truvada^®
(emtricitabine and tenofovir disoproxil fumarate).

                         Three Months Ended          
                          March 31,
                          2013          2012           % Change
Antiviral product sales   $ 2,061,078    $ 1,925,806    7    %
Atripla                   877,073        887,596        (1   )%
Truvada                   700,242        758,263        (8   )%
Viread                    210,332        191,693        10   %
Complera/Eviplera         148,189        52,180         184  %
Stribild                  92,148         —              —
                                                             

Cardiovascular Product Sales

Cardiovascular product sales increased 26 percent to $214.4 million for the
first quarter of 2013, up from $170.5 million for the first quarter of 2012
driven primarily by strong Letairis^® (ambrisentan) sales.

                              Three Months Ended      
                               March 31,
                               2013        2012         % Change
Cardiovascular product sales   $ 214,393    $ 170,489    26   %
Letairis                       118,107      87,288       35   %
Ranexa                         96,286       83,201       16   %
                                                              

Operating Expenses and Other

Non-GAAP research and development (R&D) expenses increased due to Gilead's
continued investment in its product pipeline, particularly in liver disease
and oncology. Non-GAAP selling, general and administrative (SG&A) expenses
increased primarily due to expenses to support the ongoing growth of Gilead's
business.

Interest expense decreased primarily due to the repayment of bank debt issued
in connection with the acquisition of Pharmasset Inc. Gilead repaid bank debt
totaling $1.40 billion in 2012. The change in other income (expense), net was
due primarily to a $40.1 million loss during the first quarter of 2012
resulting from the Greek government's debt restructuring.

                                                    Three Months Ended
                                                     March 31,
                                                     2013         2012
Non-GAAP research and development expenses ^(1)      $ 459,976     $ 331,338
Non-GAAP selling, general and administrative         $ 333,064     $ 307,741
expenses ^(1)
                                                                   
Interest expense                                     $ (81,787 )   $ (97,270 )
Other income (expense), net                          $ (3,324  )   $ (34,085 )

^(1) Non-GAAP R&D expenses and SG&A expenses exclude the impact of
acquisition-related, restructuring and stock-based compensation expenses where
applicable.

Net Foreign Currency Exchange Impact

The net foreign currency exchange impact on first quarter 2013 product sales
and pre-tax earnings was an unfavorable $7.3 million and $6.3 million,
respectively, compared to the first quarter of 2012.

Cash, Cash Equivalents and Marketable Securities

As of March31, 2013, Gilead had $2.63 billion of cash, cash equivalents and
marketable securities compared to $2.58 billion as of December31, 2012.
During the first quarter of 2013, we generated $672.1 million in operating
cash flow, utilized $378.6 million for the acquisition of YM BioSciences Inc.
(YM) and repaid $247.1 million in debt.

Full Year 2013 Guidance Reiterated

Gilead reiterates its full year 2013 guidance which it provided on February 4,
2013:
(in millions, except percentages and per share amounts)

Net Product Sales                                           $10,000 - $10,200
Non-GAAP *
Product Gross Margin                                         74% - 76%
R&D                                                          $1,800 - $1,900
SG&A                                                         $1,550 - $1,650
Effective Tax Rate                                           26% - 28%
                                                             
Diluted EPS Impact of Acquisition-Related, Restructuring     $0.21 - $0.24
and Stock-Based Compensation Expenses

* Non-GAAP product gross margin, expense and effective tax rate exclude the
impact of acquisition-related, restructuring and stock-based compensation
expenses where applicable.

Corporate Highlights

In February, Gilead announced the completion of its acquisition of YM, a
publicly-held drug development company that was primarily focused on advancing
its lead product candidate momelotinib (formally known as CYT387), an orally
administered, once-daily, selective inhibitor of the Janus kinase (JAK)
family. The acquisition of YM represents an opportunity to add a complementary
clinical program in the area of hematologic cancers to our growing oncology
portfolio.

Also in February, Gilead announced that it reached an agreement in principle
with Teva Pharmaceuticals to settle the ongoing patent litigation concerning
the patents protecting Viread^® (tenofovir disoproxil fumarate), a treatment
for HIV infection and chronic hepatitis B infection. Under the terms of the
settlement, Teva will be allowed to launch a generic version of Viread on
December 15, 2017.

Product & Pipeline Update

Antiviral Program

In January, Gilead announced:

  *Full clinical trial results from one cohort of the ongoing Phase 2
    ELECTRON study examining a 12-week course of all-oral therapy with
    sofosbuvir (formerly GS-7977), ledipasvir (formerly GS-5885) and ribavirin
    (RBV) among genotype 1 hepatitis C virus (HCV) patients who had previously
    failed to respond to an interferon (IFN)-containing regimen, or “null
    responders.” The data confirmed that all patients in this cohort achieved
    a sustained virologic response four weeks (SVR4) after stopping therapy.
  *Initiation of the Phase 3 ION-1 study evaluating the fixed-dose
    combination of sofosbuvir/ledipasvir with and without RBV for 12 or 24
    weeks in treatment-naïve genotype 1 patients.
  *Screening of patients for the second Phase 3 ION-2 study evaluating the
    fixed-dose combination of sofosbuvir/ledipasvir with RBV for 12 weeks and
    with and without RBV for 24 weeks of therapy in treatment-experienced
    genotype 1 HCV patients.
  *Enrollment of patients in LONESTAR, a Phase 2 study evaluating
    sofosbuvir/ledipasvir for 12 weeks and sofosbuvir/ledipasvir with and
    without RBV for eight weeks in genotype 1 treatment-naïve patients. Two
    additional arms in this trial will evaluate this combination with and
    without RBV for 12 weeks in treatment-experienced genotype 1 patients who
    had previously received a protease inhibitor-containing regimen.
  *Initiation of two Phase 3 clinical trials (Study 104 and 111) evaluating a
    single tablet regimen containing tenofovir alafenamide (TAF) for the
    treatment of HIV-1 infection in treatment-naïve adults.

In February, Gilead announced:

  *Topline results from the Phase 3 FISSION study, evaluating therapy with
    either a 12-week course of sofosbuvir plus RBV or standard of care with 24
    weeks of treatment with pegylated interferon (peg-IFN) plus RBV in
    genotype 2 or 3 HCV patients. The study met its primary efficacy endpoint
    of non-inferiority of sofosbuvir plus RBV to peg-IFN plus RBV, with 67
    percent of patients achieving SVR in the sofosbuvir plus RBV treatment
    group versus 67 percent in the peg-IFN plus RBV treatment group.
  *Topline results from the Phase 3 NEUTRINO study, evaluating a 12-week
    course of therapy with sofosbuvir, RBV and peg-IFN in genotype 1, 4, 5 or
    6 HCV patients. This study met its primary efficacy endpoint of
    superiority compared to a predefined historic control SVR rate of 60
    percent, with 90 percent of patients achieving a sustained virologic
    response 12 weeks after completing therapy.
  *Topline results from the Phase 3 FUSION study evaluating 12- and 16-week
    courses of therapy with the once-daily sofosbuvir plus RBV in
    treatment-experienced patients with genotype 2 or 3 chronic HCV infection.
    The study met its primary efficacy endpoint of superiority compared to a
    predefined historic control SVR rate of 25 percent.

In March, Gilead announced:

  *Results from a 24-week Phase 2 study (Study 102) evaluating a once-daily
    single tablet regimen containing TAF for the treatment of HIV-1 infection.
    A regimen of TAF 10 mg/elvitegravir 150 mg/cobicistat 150 mg/emtricitabine
    200 mg was found to be similar to Stribild based on the percentage of
    patients with HIV RNA levels less than 50 copies/mL at 24 weeks of
    treatment.
  *The Committee for Medicinal Products for Human Use, the scientific
    committee of the European Medicines Agency, adopted a positive opinion on
    the company’s Marketing Authorisation Application for the once-daily,
    single tablet regimen Stribild for the treatment of HIV-1 infection in
    adult patients who are antiretroviral-naïve or are infected with HIV-1
    without known mutations associated with resistance to any of the three
    antiretroviral agents in Stribild.
  *An update on the Phase 3 ION-1 study evaluating a once-daily fixed-dose
    combination of sofosbuvir/ledipasvir with and without RBV for 12 or 24
    weeks in treatment naïve genotype 1 HCV patients. A planned review by the
    study's Data and Safety Monitoring Board of safety data from patients in
    all four arms and of SVR4 rates from patients in the two 12-week duration
    arms concluded that the trial should continue without modification. This
    recommendation was based upon the observed SVR4 rates exceeding the
    predefined threshold and the absence of significant safety issues.
    Enrollment of the remaining patients in ION-1 is underway.
  *Completion of enrollment in the second Phase 3 ION-2 study evaluating the
    fixed-dose combination of sofosbuvir/ledipasvir with RBV for 12 weeks, and
    with and without RBV for 24 weeks, in treatment-experienced genotype 1 HCV
    patients.

Cardiovascular Program

In March, Gilead announced data from the Phase 4 TERISA (Type 2 Diabetes
Evaluation of Ranolazine In Subjects With Chronic Stable Angina) study, which
demonstrated that the addition of ranolazine to background antianginal therapy
in chronic angina patients with type 2 diabetes significantly reduced the
frequency of weekly angina episodes compared to background antianginal therapy
alone.

Conference Call

At 4:30 p.m. Eastern Time today, Gilead's management will host a conference
call and a simultaneous webcast to discuss results from its first quarter 2013
as well as provide a general business update. To access the webcast live via
the internet, please connect to the company's website at www.gilead.com 15
minutes prior to the conference call to ensure adequate time for any software
download that may be needed to hear the webcast. Alternatively, please call
1-866-318-8617 (U.S.) or 1-617-399-5136 (international) and dial the
participant passcode 81259571 to access the call.

A replay of the webcast will be archived on the company's website for one
year, and a phone replay will be available approximately two hours following
the call through May 5, 2013. To access the phone replay, please call
1-888-286-8010 (U.S.) or 1-617-801-6888 (international) and dial the
participant passcode 57408121.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and
commercializes innovative therapeutics in areas of unmet medical need. The
company's mission is to advance the care of patients suffering from
life-threatening diseases worldwide. Headquartered in Foster City, California,
Gilead has operations in North America, Europe and Asia-Pacific.

Non-GAAP Financial Information

Gilead has presented certain financial information in accordance with U.S.
generally accepted accounting principles (GAAP) and also on a non-GAAP basis.
Management believes this non-GAAP information is useful for investors, taken
in conjunction with Gilead's GAAP financial statements, because management
uses such information internally for its operating, budgeting and financial
planning purposes. Non-GAAP information is not prepared under a comprehensive
set of accounting rules and should only be used to supplement an understanding
of Gilead's operating results as reported under GAAP. A reconciliation between
GAAP and non-GAAP financial information is provided in the table on pages 8
and 9.

Forward-looking Statements

Statements included in this press release that are not historical in nature
are forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Gilead cautions readers that forward-looking
statements are subject to certain risks and uncertainties that could cause
actual results to differ materially. These risks and uncertainties include:
Gilead's ability to achieve its anticipated full year 2013 financial results;
Gilead's ability to sustain growth in revenues for its antiviral,
cardiovascular and respiratory franchises; availability of funding for state
AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP
purchases driven by federal and state grant cycles which may not mirror
patient demand and may cause fluctuations in Gilead's earnings; the
possibility of unfavorable results from clinical trials involving sofosbuvir,
the fixed-dose combination of sofosbuvir/ledipasvir and single tablet regimens
containing TAF for the treatment of HIV-1 infection; the levels of inventory
held by wholesalers and retailers which may cause fluctuations in Gilead's
earnings; Gilead's ability to submit new drug applications for new product
candidates in the timelines currently anticipated, including sofosbuvir and
sofosbuvir/ledipasvir for the treatment of HCV; Gilead's ability to receive
regulatory approvals in a timely manner or at all, for new and current
products, including Stribild from the European Medicines Agency; Gilead's
ability to successfully commercialize its products, including Stribild;
Gilead's ability to successfully develop its respiratory, cardiovascular and
oncology/inflammation franchises; safety and efficacy data from clinical
studies may not warrant further development of Gilead's product candidates,
including sofosbuvir; the potential for additional austerity measures in
European countries that may increase the amount of discount required on
Gilead's products; fluctuations in the foreign exchange rate of the U.S.
dollar that may cause an unfavorable foreign currency exchange impact on
Gilead's future revenues and pre-tax earnings; Gilead's ability to advance
YM's product pipeline; and other risks identified from time to time in
Gilead's reports filed with the U.S. Securities and Exchange Commission. In
addition, Gilead makes estimates and judgments that affect the reported
amounts of assets, liabilities, revenues and expenses and related disclosures.
Gilead bases its estimates on historical experience and on various other
market-specific and other relevant assumptions that it believes to be
reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. Actual results may differ
significantly from these estimates. You are urged to consider statements that
include the words may, will, would, could, should, might, believes, estimates,
projects, potential, expects, plans, anticipates, intends, continues,
forecast, designed, goal, or the negative of those words or other comparable
words to be uncertain and forward-looking. Gilead directs readers to its press
releases, Annual Report on Form 10-K for the year ended December 31, 2012 and
other subsequent disclosure documents filed with the Securities and Exchange
Commission. Gilead claims the protection of the Safe Harbor contained in the
Private Securities Litigation Reform Act of 1995 for forward-looking
statements. All forward-looking statements are based on information currently
available to Gilead, and Gilead assumes no obligation to update any such
forward-looking statements.

 Gilead owns or has rights to various trademarks, copyrights and trade names
 used in our business, including the following: GILEAD^®, GILEAD SCIENCES^®,
TRUVADA^®, VIREAD^®, HEPSERA^®, AMBISOME^®, EMTRIVA^®, COMPLERA^®, EVIPLERA^®,
          STRIBILD^®, VISTIDE^®, LETAIRIS^®, RANEXA^® and CAYSTON^®.
ATRIPLA^® is a registered trademark belonging to Bristol-Myers Squibb& Gilead
                                Sciences, LLC.

For more information on Gilead Sciences, Inc., please visit www.gilead.com or
call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

                                               
GILEAD SCIENCES, INC.

CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

(in thousands, except per share amounts)
                                                 
                                                 Three Months Ended
                                                 March 31,
                                                 2013           2012
Revenues:
Product sales                                    $ 2,393,568     $ 2,208,342
Royalty, contract and other revenues             138,067        74,107      
Total revenues                                   2,531,635      2,282,449   
Costs and expenses:
Cost of goods sold                               634,448         580,931
Research and development                         497,632         458,211
Selling, general and administrative              374,296        443,121     
Total costs and expenses                         1,506,376      1,482,263   
Income from operations                           1,025,259       800,186
Interest expense                                 (81,787     )   (97,270     )
Other income (expense), net                      (3,324      )   (34,085     )
Income before provision for income taxes         940,148         668,831
Provision for income taxes                       222,438        231,300     
Net income                                       717,710         437,531
Net loss attributable to noncontrolling          4,476          4,425       
interest
Net income attributable to Gilead                $ 722,186      $ 441,956   
Net income per share attributable to Gilead      $ 0.47         $ 0.29      
common stockholders - basic ^(1)
Net income per share attributable to Gilead      $ 0.43         $ 0.28      
common stockholders - diluted ^(1)
Shares used in per share calculation - basic     1,521,372      1,512,572   
^(1)
Shares used in per share calculation - diluted   1,665,060      1,554,776   
^(1)

^(1) Net income per share and the number of shares used in the per share
calculations for all periods presented reflect the two-for-one stock split in
the form of a stock dividend declared on December 10, 2012 which took effect
on January 25, 2013.


GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

(unaudited)

(in thousands, except percentages and per share amounts)
                                                   
                                                     Three Months Ended
                                                     March 31,
                                                     2013         2012
Cost of goods sold reconciliation:
GAAP cost of goods sold                              $ 634,448     $ 580,931
Stock-based compensation expenses                    (1,841    )   (2,101    )
Acquisition related-amortization of purchased        (21,264   )   (15,836   )
intangibles
Non-GAAP cost of goods sold                          $ 611,343    $ 562,994 
                                                                   
Product gross margin reconciliation:
GAAP product gross margin                            73.5      %   73.7      %
Stock-based compensation expenses                    0.1       %   0.1       %
Acquisition related-amortization of purchased        0.9       %   0.7       %
intangibles
Non-GAAP product gross margin^(1)                    74.5      %   74.5      %
                                                                   
Research and development expenses reconciliation:
GAAP research and development expenses               $ 497,632     $ 458,211
Stock-based compensation expenses                    (26,875   )   (118,623  )
Restructuring expenses                               (4,757    )   (5,514    )
Acquisition related-contingent consideration         (6,024    )   (2,736    )
remeasurement
Non-GAAP research and development expenses           $ 459,976    $ 331,338 
                                                                   
Selling, general and administrative expenses
reconciliation:
GAAP selling, general and administrative expenses    $ 374,296     $ 443,121
Stock-based compensation expenses                    (33,051   )   (121,944  )
Restructuring expenses                               (744      )   (3,156    )
Acquisition related-transaction costs                (7,156    )   (10,280   )
Acquisition related-amortization of purchased        (281      )   —         
intangibles
Non-GAAP selling, general and administrative         $ 333,064    $ 307,741 
expenses
                                                                   
Operating margin reconciliation:
GAAP operating margin                                40.5      %   35.1      %
Stock-based compensation expenses                    2.4       %   10.6      %
Restructuring expenses                               0.2       %   0.4       %
Acquisition related-transaction costs                0.3       %   0.5       %
Acquisition related-amortization of purchased        0.9       %   0.7       %
intangibles
Acquisition related-contingent consideration         0.2       %   0.1       %
remeasurement
Non-GAAP operating margin^(1)                        44.5      %   47.3      %
                                                                   
Interest expense reconciliation:
GAAP interest expense                                $ (81,787 )   $ (97,270 )
Acquisition related-transaction costs                —            7,333     
Non-GAAP interest expense                            $ (81,787 )   $ (89,937 )
                                                                   
Net income attributable to Gilead reconciliation:
GAAP net income attributable to Gilead, net of tax   $ 722,186     $ 441,956
Stock-based compensation expenses                    45,380        229,604
Restructuring expenses                               5,368         6,346
Acquisition related-transaction costs                7,156         12,891
Acquisition related-amortization of purchased        15,829        11,590
intangibles
Acquisition related-contingent consideration         6,024        2,002     
remeasurement
Non-GAAP net income attributable to Gilead, net of   $ 801,943    $ 704,389 
tax
                                                                   
Diluted earnings per share^(2) reconciliation:
GAAP diluted earnings per share                      $ 0.43        $ 0.28
Stock-based compensation expenses                    0.03          0.15
Restructuring expenses                               0.00          0.00
Acquisition related-transaction costs                0.00          0.01
Acquisition related-amortization of purchased        0.01          0.01
intangibles
Acquisition related-contingent consideration         0.00         0.00      
remeasurement
Non-GAAP diluted earnings per share^(1)              $ 0.48       $ 0.45    
                                                                   
Shares used in per share calculation (diluted)^(2)
reconciliation:
GAAP shares used in per share calculation            1,665,060     1,554,776
(diluted)
Share impact of current stock-based compensation     (1,716    )   (4,076    )
rules
Non-GAAP shares used in per share calculation        1,663,344    1,550,700 
(diluted)
                                                                   
Non-GAAP adjustment summary:
Cost of goods sold adjustments                       $ 23,105      $ 17,937
Research and development expenses adjustments        37,656        126,873
Selling, general and administrative expenses         41,232        135,380
adjustments
Interest expense adjustments                         —            7,333     
Total non-GAAP adjustments before tax                101,993       287,523
Income tax effect                                    (22,236   )   (25,090   )
Total non-GAAP adjustments after tax                 $ 79,757     $ 262,433 

^(1) Amounts may not sum due to rounding.
^(2) The earnings per share calculation and the number of shares used in the
per share calculation reflect the two-for-one stock split in the form of a
stock dividend declared on December 10, 2012 which took effect on January 25,
2013.


GILEAD SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)
                                                               
                                                March 31,   December 31,
                                                2013              2012^(1)
                                                (unaudited)
Cash, cash equivalents and marketable           $  2,631,030      $ 2,582,086
securities
Accounts receivable, net                        1,945,189         1,751,388
Inventories                                     1,799,618         1,744,982
Property, plant and equipment, net              1,125,794         1,100,259
Intangible assets, net                          12,077,548        11,736,393
Goodwill                                        1,188,157         1,060,919
Other assets                                    1,444,332        1,263,811
Total assets                                    $  22,211,668    $ 21,239,838
                                                                  
Current liabilities                             $  4,290,215      $ 4,270,020
Long-term liabilities                           7,528,980         7,418,949
Stockholders’ equity^(2)                        10,392,473       9,550,869
Total liabilities and stockholders’ equity      $  22,211,668    $ 21,239,838
                                                                    

^(1) Derived from the audited consolidated financial statements as of December
31, 2012.
^(2) As of March 31, 2013, there were 1,524,383 shares of common stock issued
and outstanding.


GILEAD SCIENCES, INC.

PRODUCT SALES SUMMARY

(unaudited)

(in thousands)
                                               
                                                 Three Months Ended
                                                 March 31,
                                                 2013           2012
Antiviral products:
Atripla – U.S.                                   $ 553,826       $ 562,044
Atripla – Europe                                 278,215         270,696
Atripla – Other International                    45,032         54,856
                                                 877,073        887,596
                                                                 
Truvada – U.S.                                   307,861         373,326
Truvada – Europe                                 332,027         321,876
Truvada – Other International                    60,354         63,061
                                                 700,242        758,263
                                                                 
Viread – U.S.                                    82,628          81,656
Viread – Europe                                  88,206          84,885
Viread – Other International                     39,498         25,152
                                                 210,332        191,693
                                                                 
Complera / Eviplera – U.S.                       103,297         48,639
Complera / Eviplera – Europe                     38,962          3,267
Complera / Eviplera – Other International        5,930          274
                                                 148,189        52,180
                                                                 
Stribild – U.S.                                  91,978          —
Stribild – Other International                   170            —
                                                 92,148         —
                                                                 
Hepsera – U.S.                                   12,950          12,809
Hepsera – Europe                                 11,223          13,965
Hepsera – Other International                    2,250          2,523
                                                 26,423         29,297
                                                                 
Emtriva – U.S.                                   4,529           4,093
Emtriva – Europe                                 1,751           1,811
Emtriva – Other International                    391            873
                                                 6,671          6,777
                                                                 
Total Antiviral products – U.S.                  1,157,069       1,082,567
Total Antiviral products – Europe                750,384         696,500
Total Antiviral products – Other International   153,625        146,739
                                                 2,061,078      1,925,806
                                                                 
Letairis                                         118,107         87,288
Ranexa                                           96,286          83,201
AmBisome                                         85,275          84,764
Other products                                   32,822         27,283
                                                 332,490        282,536
                                                                 
Total product sales                              $ 2,393,568    $ 2,208,342

Contact:

Gilead Sciences, Inc.
Robin Washington, 650-522-5688 (Investors)
Patrick O'Brien, 650-522-1936 (Investors)
Amy Flood, 650-522-5643 (Media)
 
Press spacebar to pause and continue. Press esc to stop.